Compare Regeneron Pharmaceuticals Inc (REGN) vs Vertiv Holdings Co (VRT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Vertiv Holdings Co — how do they compare? Regeneron Pharmaceuticals Inc trades at $807.6 (market cap $83.43B), while Vertiv Holdings Co trades at $262.49 (market cap $111.97B). The key difference: Vertiv Holdings Co is the larger of the two by market cap, and Regeneron Pharmaceuticals Inc pays the higher dividend (0.46%). Which is the better fit depends on your goals.
| REGN | VRT | |
|---|---|---|
Market Cap | $83.43B | $111.97B |
Sector | Health | Technology |
52-Week High | $852.03 | $376.23 |
52-Week Low | $555.51 | $134.84 |
Enterprise Value | $78.14B | $112.19B |
Dividend Yield | 0.46% | 0.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.
Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.
Vertiv Holdings (VRT) trades at $290.83, up 3.67% with strong technical bullish signals and consistent earnings beats. The company demonstrates robust fundamentals with 15.09% net margins and 43.94% ROE, supported by data center infrastructure demand. Recent acquisition of UtilityInnovation Group for $1.45 billion positions VRT for AI-driven growth, while analyst consensus shows 95% buy ratings with a $355.17 price target.
Outlook remains positive given AI infrastructure tailwinds and strong execution, though elevated valuation multiples (P/E 65.8) and RSI overbought conditions warrant caution. The stock offers growth exposure to data center expansion but faces competition and execution risks on recent acquisitions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Vertiv Holdings Co
Vertiv is a global leader in critical digital infrastructure, providing essential power, cooling, and IT management solutions for data centers, communication networks, and industrial facilities. As the primary provider of advanced thermal management and liquid cooling systems, Vertiv is a central player in the AI revolution, enabling the extreme density and power requirements of next-generation GPU-driven computing.
Read more on VRT →
